每经AI快讯，科伦药业（SZ 002422，收盘价：36.46元）发布公告称，2025年8月29日下午，科伦药业 接受东海证券等投资者调研，科伦药业副总经理兼财务总监赖德贵等参与接待，并回答了投资者提出的 问题。 每经头条（nbdtoutiao）——个人消费贷贴息明日开闸！贷30万元最多可享贴息3000元，一文读懂→ 2025年1至6月份，科伦药业的营业收入构成为：医药制造业占比89.66%，研发项目占比7.01%，其他业 务占比3.33%。 （记者 胡玲） ...

Sales Performance - The company reported a significant increase in sales for the dual-chamber bags, with a year-on-year growth of 64% in the first half of the year, and expects to maintain strong growth throughout the year [3] - The three-chamber bags for parenteral nutrition saw a year-on-year increase of 55.6% in the first half, with expectations for continued growth [3] Production and Cost Efficiency - The company has two high-speed production lines operational, achieving a cost reduction of approximately 20% compared to previous production methods [4] - AI integration in production has improved fermentation efficiency by 3% to 5%, with plans to expand AI applications across more product lines [11] Market Dynamics - Over 70% of the national market for infusion products is expected to complete volume-based procurement by the end of the year, stabilizing the core market for the company [5] - The competitive landscape for basic infusion products remains stable, benefiting from national and local volume-based procurement policies [6] Generic Drug Business - The 11th round of procurement affects about 14 products, mostly newly approved by the company, with minimal impact on existing products [7] - The generic drug segment has seen stable revenue and profit growth over the past three years, supported by a cost leadership strategy [8] Antibiotic Intermediates - Demand for antibiotic intermediates is stable, with specific products like erythromycin maintaining a balanced supply-demand situation [9] - The company anticipates a gradual stabilization of prices for penicillin products, despite a current decline in demand [10] Research and Development - R&D expenses for the first half of the year amounted to approximately 1.048 billion, with 35% allocated to generic drugs and 60% to innovative drugs [14] - The company is focusing on innovative drug development in non-infusion formulations, targeting areas such as anesthesia and central nervous system disorders [15]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, with a focus on the challenges faced in its infusion, generic drugs, and raw materials segments, while highlighting growth opportunities from innovative product launches [1][2]. Revenue and Profit Summary - The company’s total revenue for the first half of 2025 was 9.083 billion yuan, a decrease of 23.2% year-on-year, with a net profit attributable to the parent company of 1.001 billion yuan, down 44.41% [1]. - In Q2 alone, revenue was 4.693 billion yuan, reflecting a year-on-year decline of 16.3%, and net profit was 416 million yuan, down 46.2% [1]. Business Segment Performance - **Infusion Segment**: Revenue was 3.750 billion yuan, a decline of 19.65% year-on-year. The company is transitioning to fully closed infusion systems, with the market share of closed infusion products increasing by 0.39 percentage points [2]. - **Non-Infusion Formulations**: Revenue reached 1.955 billion yuan, down 3.18% year-on-year. The sales of plastic water injections decreased by 11.96% due to reduced demand for glucose injections and the failure to win bids in national procurement [2]. - **Intermediate and Raw Materials**: Revenue from antibiotic intermediates and raw materials was 2.282 billion yuan, down 30.29% year-on-year, primarily due to market demand fluctuations [2]. International Business - The company achieved overseas revenue of 1.130 billion yuan, a decline of 39.69% year-on-year, mainly due to a decrease in overseas licensing income [3]. R&D and Innovation - The company is advancing its R&D pipeline with a dual focus on core business and innovative exploration. The innovative product Jiatailai has been launched, and further exploration for its use in treating various solid tumors is ongoing [3]. - Collaborations with Merck are progressing on 14 clinical studies for sac-TMT as a monotherapy or in combination with other drugs for multiple cancer types [3]. Investment Outlook - The company’s infusion and raw material intermediate businesses are expected to reach a bottom, with ongoing progress in the pipeline and accelerated sales of innovative products. Projected net profits for 2025-2027 are 1.675 billion, 2.248 billion, and 2.716 billion yuan, with year-on-year growth rates of -43%, 34%, and 21% respectively [4].

证券代码：002422 证券简称：科伦药业 公告编号：2025-063 四川科伦药业股份有限公司 关于公司 2025 年度中期利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第八届董事会第八次会议、第八届监事会第七次会议审议通过了《关于公司 2025 年度中期利润分配预案的议案》。现将相关情况公告如下： 二、利润分配方案的合法性、合规性和合理性 本次利润分配预案符合《公司法》《上市公司监管指引第 3 号——上市公司 现金分红》《公司章程》及《未来三年股东回报规划（2024-2026）》等规定， 符合公司确定的利润分配政策、股东回报规划，该方案合法、合规。本次利润分 配预案充分考虑了公司 2025 年半年度盈利状况、公司未来发展资金需求以及股 东投资回报等综合因素，符合公司和全体股东的利益，具备合理性。该分配方案 的实施不会对公司日常经营造成不良影响。 三、履行决策程序情况及意见 （一）董事会审议程序 对，0 票弃权审议通过了《关于公司 2025 年度中期利润 ...

Core Viewpoint - The article highlights the strategic adjustments made by prominent fund managers in response to the market's structural characteristics, focusing on sectors like AI, innovative pharmaceuticals, and consumer goods, while also indicating a clear divergence in the consumer sector's performance [2][3][4]. Group 1: Fund Manager Strategies - Prominent fund managers have collectively increased their positions in high-growth sectors such as AI and innovative pharmaceuticals while making structural adjustments within the consumer sector [2]. - The technology and pharmaceutical sectors have emerged as core allocation directions, with significant investments in companies like BYD (increased by 184.78%) and Alibaba (increased by 161.10%) [2]. - Fund managers are focusing on "hard technology" in the tech sector, with AI computing and robotics becoming key investment areas [4]. Group 2: Consumer Sector Dynamics - The consumer sector has shown significant structural differentiation, with fund managers displaying contrasting attitudes towards traditional liquor and new consumption trends [3]. - Some fund managers have increased their holdings in traditional liquor stocks like Wuliangye and Moutai, while others have reduced their positions in these stocks, indicating a shift towards new consumption opportunities [3][4]. - The performance of consumer companies has influenced fund adjustments, with companies like Yili achieving strong revenue growth while others like Yanghe experienced profit declines [4]. Group 3: Future Outlook - Looking ahead to the third quarter, there is optimism regarding the innovative pharmaceutical sector, driven by global collaborations and anticipated clinical data disclosures [5]. - The consumer healthcare sector is expected to continue benefiting from rising health awareness among residents, with demand for home medical devices projected to grow steadily due to an aging population [5]. - The overall economic environment is seen as favorable for investment, although structural pressures may persist, with policies aimed at reducing excessive competition likely to improve corporate profitability [5].

格隆汇8月28日丨科伦药业(002422.SZ)公布2025年半年度报告，上半年公司实现营业收入90.83亿元，同 比下降23.20%；归属于上市公司股东的净利润10.01亿元，同比下降44.41%；归属于上市公司股东的扣 除非经常性损益的净利润9.85亿元，同比下降43.79%；基本每股收益0.63元；拟向全体股东每10股派发 现金红利1.26元(含税)。 ...

四川科伦药业股份有限公司 独立董事工作制度 （2025年8月修订） 根据中国证券监督管理委员会（以下简称"中国证监会"）颁布的 《上市公司独立董事管理办法》《上市公司治理准则》及国家有关法律、法规、 部门规章、其他规范性文件和公司章程的有关规定，为进一步完善四川科伦药 业股份有限公司（以下简称"公司"）的法人治理结构，改善董事会结构，强化 对内部董事及经理层的约束和监督机制，保护中小股东及债权人的利益，促进 公司的规范运作，特制定本制度。 独立董事是指不在公司担任除董事及董事会专门委员会委员外的其 他职务，并与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或 者其他可能影响其进行独立客观判断的关系的董事。 公司董事会成员中应当有1/3以上独立董事，其中至少有一名会计专 业人士。 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应当忠实履行 职务，维护公司利益，尤其要关注社会公众股股东的合法权益不受损害。独立 董事应当独立公正地履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 若发现所审议事项存在影响其独立性的情况，应当向公司申明并实行回避。 任职期间出现明显影响独立性情形的，应 ...

四川科伦药业股份有限公司 董事会环境、社会及治理（ESG）委员会实施细则 第五条 委员会任期与董事会成员任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务或出现不适宜担任委员的情形，自动失 去委员资格，并由董事会根据上述第三至第四条的规定补足委员人数。 委员辞职导致委员会中独立董事占比不符合本实施细则第三条规定的，在新 的委员就任前，原委员仍应继续履行职责，法律法规、深圳证券交易所或者《公 司章程》另有规定的除外。 （2025年8月修订） 第六条 委员会设主任委员（召集人）一名，由董事长提名具有管理公司 环境、社会及治理专业能力的董事担任。 第一章 总则 第七条 委员会下设 ESG 工作组，负责委员会日常事务及执行委员会决议， 包括但不限于筹备委员会会议、执行公司环境、社会及治理的具体工作。 第一条 为进一步完善四川科伦药业股份有限公司（以下简称"公司"） 的治理架构，提高公司环境、社会和治理（ESG）水平及可持续发展工作的决策 效率。根据《中华人民共和国公司法》《上市公司治理准则》及其他有关规定， 公司董事会特设立环境、社会及治理（ESG）委员会（以下简称"委员会"）， 并制定本工作细 ...

四川科伦药业股份有限公司 股东会议事规则 （2025年8月修订） 第一章 总则 第一条 目的 为了保护公司和股东的权益，规范公司股东会的召集、提案、通知、召开 及表决机制，保障公司所有股东公平、合法的行使股东权利及履行股东义务， 依照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）和国家有关法律法规、规范性文件、 深圳证券交易所业务规则以及《公司章程》，制定《四川科伦药业股份有限公 司股东会议事规则》（以下简称"本规则"）。 第二条 效力 本规则自生效之日起，即成为规范公司股东会的组织与行为，规范公司股 东权利与义务的具有法律约束力的文件。 第二章 股东 第三条 股份托管 公司依法在中国证券登记结算有限责任公司（以下简称"证券登记公司"） 办理股份存管，公司将根据与证券登记公司签订的证券登记及服务协议，定期 查询主要股东资料以及主要股东的持股变更（包括股权的出质），及时掌握公 司的股权结构。 公司依据证券登记公司提供的凭证建立股东名册，股东名册是证明股东持 有公司股份的充分证据。股东按其所持有股份的类别享有权利，承担义务；持 有同一类别股份的股东，享有同 ...

四川科伦药业股份有限公司 董事会议事规则 （2025年8月修订） 第一条 目的 为了保护公司和股东的权益，规范董事的行为，理顺公司管理体制，明晰 董事会的职责权限，建立规范化的董事会组织架构及运作程序，保障公司经营 决策高效、有序地进行，依照《中华人民共和国公司法》及国家有关法律法规、 深圳证券交易所相关业务规则及公司章程的有关规定，制定《四川科伦药业股 份有限公司董事会议事规则》（下称"本规则"）。 第二条 效力 本规则自生效之日起，即成为规范公司董事会的召集、召开、议事及表决 程序的具有约束力的法律文件。 第三条 任职资格 董事为自然人，无需持有公司股份。但是，下列人员不得担任董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩 序，被判处刑罚，执行期满未逾5年，或者因犯罪被剥夺政治权利，执行期满未 逾5年，被宣告缓刑的，自缓刑考验期满之日起未逾二年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企 业的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾3年； （四）担任因违法被吊销营业执照、责令关闭的公司、企业的法定 ...